Poractant Alfa

Brand names: Curosurf
Drug class: Antineoplastic Agents

Usage of Poractant Alfa

Respiratory Distress Syndrome (RDS)

Treatment (rescue) of RDS (hyaline membrane disease) in premature neonates (designated an orphan drug by FDA for this use).

Prevention† [off-label] of RDS in infants at high risk for RDS.

Relate drugs

How to use Poractant Alfa

General

  • Observe clinical status and monitor systemic oxygenation frequently; decrease inspired oxygen concentrations and ventilator pressures gradually to prevent hyperoxia.
  • Following completion of dosing procedure, resume usual ventilator management and clinical care. Do not suction airways for 1 hour after dosing unless substantial obstruction occurs. (See Experience of Supervising Clinician under Cautions.)

    • Administration

    Intratracheal Administration

    Administer only by intratracheal instillation using specialized techniques. Consult manufacturer’s labeling or specialized references for guidelines on administration techniques.

    Allow drug to reach room temperature before administration. Gently invert vial to obtain a uniform suspension; do not shake.

    Contains no preservatives; discard unused portion.

    Dosage

    Available as poractant alfa; dosage expressed in terms of phospholipids.

    Each mL of the commercially available formulation contains 80 mg of phospholipids (including 54 mg of phosphatidylcholine, of which 30.5 mg is dipalmitoyl phosphatidylcholine) and 1 mg of surfactant proteins (SP-B, SP-C).

    Pediatric Patients

    Treatment of RDS Intratracheal

    Premature neonates: 2.5 mL/kg (200 mg/kg) of birthweight.

    Administer up to 2 repeat doses (1.25 mL/kg of birth weight), given at 12-hour intervals, if neonate remains intubated and respiratory manifestations of RDS persist or worsen.

    Prevention of RDS† [off-label] Intratracheal

    100 or 200 mg/kg, given as a single dose within 10 minutes of birth.

    Prescribing Limits

    Pediatric Patients

    Treatment of RDS Intratracheal

    Premature neonates: Total dosage (initial and repeat doses) should not exceed 5 mL/kg. Safety and efficacy not established for administration of >3 doses (1 initial and 2 repeat doses), administration more frequently than every 12 hours, and initiation of therapy >15 hours after diagnosis of RDS.

    Warnings

    Contraindications

  • No known contraindications.

    • Warnings/Precautions

    Warnings

    Experience of Supervising Clinician

    Use only by clinicians experienced in resuscitation, stabilization, and general care of premature neonates.

    Respiratory Effects

    Therapy can rapidly affect oxygenation and lung compliance. Perform frequent clinical and laboratory assessments; modify oxygen and ventilatory support in response to respiratory changes.

    Transient episodes of decreased oxygen saturation reported. If this occurs, discontinue administration and initiate appropriate measures to alleviate the condition; following stabilization, resume therapy and monitor appropriately.

    Cardiovascular Effects

    Transient episodes of bradycardia and hypotension reported. If these occur, discontinue administration and initiate appropriate measures to alleviate the condition; following stabilization, resume therapy and monitor appropriately.

    Endotracheal Tube Complications

    Transient endotracheal tube blockage, reflux of surfactant into endotracheal tube, and airway obstruction reported. If these occur, discontinue administration and initiate appropriate measures to alleviate the condition; following stabilization, resume therapy and monitor appropriately.

    General Precautions

    Concurrent Illness

    Correction of acidosis, hypotension, anemia, hypoglycemia, and hypothermia recommended prior to administration.

    Complications of Prematurity

    Therapy expected to reduce severity of RDS but will not eliminate morbidity and mortality associated with other complications of prematurity (e.g., pneumonia, septicemia, intracranial hemorrhage, patent ductus arteriosus).

    Use with Investigational Treatments for RDS

    Safety and efficacy in conjunction with investigational therapies for RDS (e.g., high-frequency ventilation) not established.

    Specific Populations

    Pregnancy

    Not intended for use in adults.

    Lactation

    Not intended for use in adults.

    Common Adverse Effects

    Transient bradycardia, hypotension, endotracheal tube blockage, decreased oxygen saturation.

    What other drugs will affect Poractant Alfa

    No drug interactions reported.

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords